Palomid 529
Code | Size | Price |
---|
TAR-T2706-5mg | 5mg | £108.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2706-1mL | 1 mL * 10 mM (in DMSO) | £112.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2706-10mg | 10mg | £125.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2706-25mg | 25mg | £177.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2706-50mg | 50mg | £269.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2706-100mg | 100mg | £399.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Palomid 529 has been used in trials studying the treatment of Age-Related Macular Degeneration.
CAS:
914913-88-5
Formula:
C24H22O6
Molecular Weight:
406.434
Pathway:
Apoptosis; PI3K/Akt/mTOR signaling
Purity:
0.9903
SMILES:
COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1
Target:
Apoptosis; mTOR
References
1. Xue Q, et al. Cancer Res, 2008, 68(22), 9551-9557.
2. Diaz R, et al. Br J Cancer 2009, 100(6), 932-940.
3. Lewis GP, et al. Invest Ophthalmol Vis Sci, 2009, 50(9), 4429-4435.
4. Xiang T, et al. Oncogene, 2011, 30(21), 2443-2450.
5. Gravina GL, et al. Endocr Relat Cancer, 2011, 18(4), 385-400.
6. Weinberg MA, et al. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes. Anticancer Drugs. 2016 Jul;27(6):475-87.
7. Zhou W, Lou W, Chen J, et al. AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest[J]. OncoTargets and Therapy. 2021, 14: 1049-1059.